🇺🇸 FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8092803

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8088926

Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/

Jenrin Discovery, LLC · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8088798

Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

Jensen Discovery, Inc. · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8088809

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders,

Jenrin Discovery, LLC · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8084614

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. · Granted Tue Dec 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8071807

Antagonists of prostaglandin D2 receptors

Panmira Pharmaceuticals, LLC · Granted Tue Dec 06 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8071074

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California · Granted Tue Dec 06 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8067439

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8067445

N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors

Panmira Pharmaceuticals, LLC · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8058300

Polycyclic antagonists of lysophosphatidic acid receptors

AMIRA PHARMACEUTICALS, INC. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8053448

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8048844

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8048902

Antagonists of lysophosphatidic acid receptors

AMIRA PHARMACEUTICALS, INC. · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8048418

Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and V

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8049015

Heteroaryl antagonists of prostaglandin D2 receptors

Panmira Pharmaceuticals, LLC · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8039489

Guanidine-containing compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Oct 18 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8034946

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Oct 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8034826

Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors

Panmira Pharmaceuticals, LLC · Granted Tue Oct 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8017617

Amidine-containing compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Sep 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8017783

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Sep 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8013152

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Sep 06 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7960385

Guanidine-containing compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Jun 14 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7947710

Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance, Inc. · Granted Tue May 24 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7943131

Methods for protecting and regenerating bone marrow using CXCR3 agonists and antagonists

GENERAL REGENERATIVES, LTD. · Granted Tue May 17 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted